Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
about
Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disordersSchizophrenia: more dopamine, more D2 receptorsAlterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant SchizophreniaAntipsychotic dosing: found in translationHistory of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophreniaApomorphine and the dopamine hypothesis of schizophrenia: a dilemma?Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug responseModel-based parametric study of frontostriatal abnormalities in schizophrenia patientsAll Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High ReceptorsAntipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionA current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.Classics in Chemical Neuroscience: Aripiprazole.Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.PET imaging demonstrates histone deacetylase target engagement and clarifies brain penetrance of known and novel small molecule inhibitors in rat.Open-label pilot study of quetiapine treatment for cannabis dependence.Psychosis pathways converge via D2high dopamine receptors.Quetiapine: dose-response relationship in schizophrenia.Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.Atypical antipsychotics and mood stabilization in bipolar disorder.Serum clozapine levels: a review of their clinical utility.Understanding antipsychotic "atypicality": a clinical and pharmacological moving targetClozapine attenuates disruptions in response inhibition and task efficiency induced by repeated phencyclidine administration in the intracranial self-stimulation procedure.The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjectsReceptor mechanisms in the treatment of schizophrenia.Movement disorder emergencies.Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder.Translating knowledge of genetics and pharmacology into improving everyday practice.Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?First- and second-generation antipsychotic medication and cognitive processing in schizophrenia.Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brainSuccessful management of clozapine adverse effects with extended (alternate day) antipsychotic dosing in a patient with schizophreniaIncreased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment.Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models.Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals.Restless legs syndrome induced by quetiapine: report of seven cases and review of the literature.
P2860
Q21129108-F5D2CA34-A8C7-4FF7-9FC8-4FCB319FA046Q24630726-71FB15AC-4992-4399-AD28-CE0BC5021D3BQ26773403-666924F4-D3A8-4827-99B1-007C749E8D5FQ26863343-3268D739-3A7A-434E-91E1-53183E807C57Q28283494-A62D0FEA-D734-460D-8156-AE7FF0193FA6Q28366409-AE46B7D8-B4B3-4714-9D0A-805DE65CA463Q28484377-4A9173D7-C1F2-4909-BCB2-7ED27DE6C365Q28748228-9C2F2409-E72A-45F5-8DE1-13C84D0AE284Q29395121-A8D965E6-A6C2-4CEB-9B9F-436DD156BB5FQ30386608-FB209F27-DF75-4508-A094-7D5019686A2AQ30667146-D9F2B420-FB5C-40E4-A05B-F2EB8040910FQ33866125-57AB2832-0A53-4F20-933A-5760E9EA62DDQ33987817-38B410CC-9F71-4258-8165-C8B92EC4A5C3Q33996824-7AD74263-A256-4381-96B5-AF54FAF89816Q34338202-2D9FF3A7-361C-42AD-8D94-36712581B9BDQ34343350-058DB8BA-3FC1-4611-A647-0C51BFAF14D4Q34512547-C57551CA-C0AC-41D2-839C-6225CD129224Q34540180-F92DE0A1-8803-4F4E-9013-28293B09838BQ34585989-40E23280-A2C3-4E00-91B9-8506A389B63AQ34653803-01A2A3FD-97CE-4E85-BC11-36B69DA4332BQ35024111-5D117B35-BD88-4C72-9129-2F3BE3606AE4Q35073763-624DDC71-3925-4B24-9F03-3DC21DE7F083Q35180807-1ED48293-D940-4A41-9EE7-E34ADCDCD3AEQ35200831-B709D73F-F5E5-4F8C-8A54-EDCC47170BA9Q35641833-229CFA63-C8C4-4FEB-8DEB-631BF467A6F2Q35647369-C9A44A85-F8C4-44E4-9F48-2B913D2281BAQ35883437-7C4A4699-4ECE-4BB6-8E8C-534A5273D712Q35975824-B5FED39F-8533-484D-85EA-3A966DDD9756Q36142165-12847CAA-9FD9-40A9-A2E2-E8F3C1A61DD1Q36158817-95EA50B9-BDF0-4837-9320-F191491EE2A9Q36183110-69AE0BAA-6DE1-42DC-A2F5-77E07A6B1E4DQ36228233-7B6E1FB7-0C20-4EAC-85A8-B765F91EECD6Q36338174-5B4FD052-6C96-41F6-ADEE-46902F9791ECQ36395488-E7382444-BDA1-4B66-A243-5FA02AEF9F00Q37354597-95912250-7C0C-48E3-BE5B-2FD8CF55C41AQ37446674-AEE5E2A3-7980-4F8E-A96D-8FC894F52EC2Q37958894-74967BA2-D46C-4ACA-B2A9-77ED85A44B87Q37983747-DFB6FA0B-F185-4723-A03B-4EAC134177F4Q38010780-3F0093AC-690F-4676-8472-9DEFEA93A92CQ38075112-7B305237-A7D7-4981-8CFF-08B3C5DFD5A8
P2860
Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Rapid release of antipsychotic ...... al of clozapine or quetiapine.
@en
Rapid release of antipsychotic ...... al of clozapine or quetiapine.
@nl
type
label
Rapid release of antipsychotic ...... al of clozapine or quetiapine.
@en
Rapid release of antipsychotic ...... al of clozapine or quetiapine.
@nl
prefLabel
Rapid release of antipsychotic ...... al of clozapine or quetiapine.
@en
Rapid release of antipsychotic ...... al of clozapine or quetiapine.
@nl
P356
P1476
Rapid release of antipsychotic ...... al of clozapine or quetiapine.
@en
P2093
P304
P356
10.1176/AJP.156.6.876
P407
P577
1999-06-01T00:00:00Z